From Self-sufficiency
Revision as of 17:44, 29 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s))

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
Routes of
Pharmacokinetic data
Metabolism Hepatic (mainly CYP3A4)[1]
Biological half-life 1.5 hours[1]
ATC code R03DC02 (WHO)
PubChem CID 115100
Chemical data
Formula C27H23N5O4
Molar mass 481.503 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. This drug works similarly to Merck & Co.'s Singulair (montelukast). It is currently under clinical trials.

Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.

Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists. There are several similar medications in the group; all appear to be equally effective.


  1. 1.0 1.1 Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S (2006). "Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma". Drug Metab Pharmacokinet. 21 (2): 133–9. doi:10.2133/dmpk.21.133. PMID 16702733.